Targeting ceramides in metabolic syndrome: recent advances and therapeutic opportunities
Authors:
- 12 October 2026
- journal article
- review article
- Published by Springer Nature in Acta Diabetologica
- p. 1-12
Abstract
No abstract availableKeywords
Funding Information
- Beijing Natural Science Foundation (7242094)
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS2021-I2M-1-016)
This publication has 83 references indexed in Scilit:
- Genetic regulation of fatty acid content in adipose tissueThe American Journal of Human Genetics, 2026
- Projecting Global Trends and Inequalities in Adult Overweight and Obesity, 2023–2040: Findings From the NCD‐RisC DatabaseObesity, 2025
- Metabolic syndrome and the risk of incident heart failure: a prospective cohort studyAmerican Journal of Preventive Cardiology, 2025
- Carotid Plaque‐Derived Small Extracellular Vesicles Mediate Atherosclerosis and Correlate With Plaque VulnerabilityMedcomm, 2025
- Mathematical model-assisted HPLC-MS/MS analysis on global, pseudo-targeted ceramide profiling and quantitation in serumAnalytica Chimica Acta, 2025
- Oxidised phosphatidylcholine induces sarcolemmal ceramide accumulation and insulin resistance in skeletal muscleDiabetologia, 2024
- Early microglial response, myelin deterioration and lethality in mice deficient for very long chain ceramide synthesis in oligodendrocytesGlia, 2022
- Hepatic loss of CerS2 induces cell division defects via a mad2‐mediated pathwayClinical and Translational Medicine, 2022
- Activation of neutral sphingomyelinase 2 through hyperglycemia contributes to endothelial apoptosis via vesicle-bound intercellular transfer of ceramidesCellular and Molecular Life Sciences, 2021
- Mammalian ceramide synthasesIUBMB Life, 2010